Advertisement

A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy

  • Michael W. Ruff
    Affiliations
    T Cell Engineering, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA

    Department of Neurology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
    Search for articles by this author
  • Elizabeth L. Siegler
    Affiliations
    T Cell Engineering, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA

    Division of Hematology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
    Search for articles by this author
  • Saad S. Kenderian
    Correspondence
    Corresponding author. Division of Hematology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905.
    Affiliations
    T Cell Engineering, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA

    Division of Hematology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA

    Department of Molecular Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA

    Department of Immunology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
    Search for articles by this author
Published:September 12, 2020DOI:https://doi.org/10.1016/j.ncl.2020.08.001

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Neurologic Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Long A.H.
        • Haso W.M.
        • Shern J.F.
        • et al.
        4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.
        Nat Med. 2015; 21: 581-590
        • Kawalekar O.U.
        • O' Connor R.S.
        • Fraietta J.A.
        • et al.
        Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells.
        Immunity. 2016; 44: 380-390
        • Neelapu S.S.
        • Locke F.L.
        • Bartlett N.L.
        • et al.
        Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
        N Engl J Med. 2017; 377: 2531-2544
        • Schuster S.J.
        • Svoboda J.
        • Chong E.A.
        • et al.
        Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
        N Engl J Med. 2017; 377: 2545-2554
        • Turtle C.J.
        • Hay K.A.
        • Hanafi L.A.
        • et al.
        Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
        J Clin Oncol. 2017; 35: 3010-3020
        • Grupp S.A.
        • Kalos M.
        • Barrett D.
        • et al.
        Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.
        N Engl J Med. 2013; 368: 1509-1518
        • Maude S.L.
        • Barrett D.
        • Teachey D.T.
        • et al.
        Managing cytokine release syndrome associated with novel T cell-engaging therapies.
        Cancer J. 2014; 20: 119-122
        • Titov A.
        • Petukhov A.
        • Staliarova A.
        • et al.
        The biological basis and clinical symptoms of CAR-T therapy-associated toxicites.
        Cell Death Dis. 2018; 9: 897
        • Santomasso B.D.
        • Park J.H.
        • Salloum D.
        • et al.
        Clinical and biological correlates of neurotoxicity associated with CAR T-cell ∖tients with B-cell Acute Lymphoblastic Leukemia.
        Cancer Discov. 2018; 8: 958-971
        • Rubin D.B.
        • Danish H.H.
        • Ali A.B.
        • et al.
        Neurological toxicities associated with chimeric antigen receptor T-cell therapy.
        Brain. 2019; 142: 1334-1348
      1. Gilbert MJ. Severe neurotoxicity in the phase 2 trial of JCAR015 in adult B-ALL (ROCKET Study): analyses of patient, protocol and product attributes. SITC Annual Meeting, National Harbor, MD: November 8-12, 2017. 102.

        • Lee D.W.
        • Santomasso B.D.
        • Locke F.L.
        • et al.
        ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
        Biol Blood Marrow Transplant. 2019; 25: 625-638
        • Gust J.
        • Hay K.A.
        • Hanafi L.A.
        • et al.
        Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells.
        Cancer Discov. 2017; 7: 1404-1419
        • Gust J.
        • Finney O.C.
        • Li D.
        • et al.
        Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy.
        Ann Neurol. 2019; 86: 42-54
        • Kochenderfer J.N.
        • Somerville R.P.T.
        • Lu T.
        • et al.
        Lymphoma remissions caused by anti-cd19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels.
        J Clin Oncol. 2017; 35: 1803-1813
        • Park J.H.
        • Rivière I.
        • Gonen M.
        • et al.
        Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia.
        N Engl J Med. 2018; 378: 449-459
        • Hunter B.D.
        • Jacobson C.A.
        CAR T-cell associated neurotoxicity: mechanisms, clinicopathologic correlates, and future directions.
        J Natl Cancer Inst. 2019; 111: 646-654
        • Novo M.
        • Ruff M.W.
        • Skrabek P.J.
        • et al.
        Axicabtagene ciloleucel chimeric antigen receptor T cell therapy in lymphoma with secondary central nervous system involvement.
        Mayo Clin Proc. 2019; 94: 2361-2364
        • Frigault M.J.
        • Dietrich J.
        • Martinez-Lage M.
        • et al.
        Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma.
        Blood. 2019; 134: 860-866
        • Torre M.
        • Solomon I.H.
        • Sutherland C.L.
        • et al.
        Neuropathology of a case with fatal CAR T-cell-associated cerebral edema.
        J Neuropathol Exp Neurol. 2018; 77: 877-882
        • Kalos M.
        • Levine B.L.
        • Porter D.L.
        • et al.
        T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.
        Sci Transl Med. 2011; 3: 95ra73
        • Maude S.L.
        • Frey N.
        • Shaw P.A.
        • et al.
        Chimeric antigen receptor T cells for sustained remissions in leukemia.
        N Engl J Med. 2014; 371: 1507-1517
        • Davila M.L.
        • Riviere I.
        • Wang X.
        • et al.
        Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.
        Sci Transl Med. 2014; 6: 224ra25
        • Norelli M.
        • Camisa B.
        • Barbiera G.
        • et al.
        Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells.
        Nat Med. 2018; 24: 739-748
        • Giavridis T.
        • van der Stegen S.J.C.
        • Eyquem J.
        • et al.
        CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade.
        Nat Med. 2018; 24: 731-738
        • Taraseviciute A.
        • Tkachev V.
        • Ponce R.
        • et al.
        Chimeric antigen receptor T cell-mediated neurotoxicity in nonhuman primates.
        Cancer Discov. 2018; 8: 750-763
        • Lee D.W.
        • Gardner R.
        • Porter D.L.
        • et al.
        Current concepts in the diagnosis and management of cytokine release syndrome.
        Blood. 2014; 124: 188-195
        • Neelapu S.S.
        • Tummala S.
        • Kebriaei P.
        • et al.
        Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.
        Nat Rev Clin Oncol. 2018; 15: 47-62